ArticleClinical breast cancer2018

Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Karen A Cadoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.